Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 1843

Original article / research
Table of Contents - Year : 2017 | Month : July | Volume : 11 | Issue : 7 | Page : EC22 - EC25

An Immunohistochemical Study of Anaplastic Lymphoma Kinase and Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Carcinoma EC22-EC25

Sonal Verma, Madhu Kumar, Malti Kumari, Raj Mehrotra, R A S Kushwaha, MadhuMati Goel, Ashutosh Kumar, Surya Kant

Dr. Madhu Kumar,
Associate Professor, Department of Pathology, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India.

Introduction: Lung cancer is one of the leading causes of cancer related death. Targeted treatment for specific markers may help in reducing the cancer related morbidity and mortality.

Aim: To study expression of Anaplastic Lymphoma Kinase (ALK)and Epidermal Growth Factor Receptor (EGFR) mutations in patients of Non-Small Cell Lung Cancer NSCLC, that are the targets for specific ALK inhibitors and EGFR tyrosine kinase inhibitors.

Materials and Methods: Total 69 cases of histologically diagnosed NSCLC were examined retrospectively for immunohistochemical expression of EGFR and ALK, along with positive control of normal placental tissue and anaplastic large cell lymphoma respectively.

Results: Of the NSCLC, Squamous Cell Carcinoma (SCC) accounted for 71.0% and adenocarcinoma was 26.1%. ALK expression was seen in single case of 60-year-old female, non-smoker with adenocarcinoma histology. EGFR expression was seen in both SCC (59.18%) and adenocarcinoma in (77.78%) accounting for 63.77% of all cases. Both ALK and EGFR mutation were mutually exclusive.

Conclusion: EGFR expression was seen in 63.77% of cases, highlighting the importance of its use in routine analysis, for targeted therapy and better treatment results. Although, ALK expression was seen in 1.45% of all cases, it is an important biomarker in targeted cancer therapy. Also, the mutually exclusive expression of these two markers need further studies to develop a diagnostic algorithm for NSCLC patients.